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In this issue, Genders et al. (2015) demonstrate in a cohort of organ transplant
recipients that betapapillomavirus seropositivity around transplantation signifi-
cantly increases the risk of developing keratinocyte carcinomas. These results
further substantiate an etiologic role of betapapillomaviruses in skin cancer and
raise prospects of anti-viral immunotherapy.
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Immunosuppressed organ transplant
recipients (OTRs) are at an increased
risk of developing cancers with viral
etiology, such as non-Hodgkin’s lym-
phoma related to Epstein–Barr virus,
Kaposi’s sarcoma caused by human
herpesvirus 8, and various anogenital
and oral cancers induced by high-risk
alphapapillomaviruses (Vajdic et al.,
2006). Especially striking is the high
prevalence of keratinocyte carcinomas
(KC), mainly due to the 4100-fold
increased incidence of cutaneous
squamous cell carcinoma (SCC). This
results in a reversal of the general SCC
to basal cell carcinoma (BCC) ratio in
Caucasians and a dominance of
SCC (Euvrard et al., 2003). The highly
increased risk of SCC in immuno-
suppressed patients points to a viral
etiology in analogy with the chara-
cteristics of other virus-induced tumors.
Papillomaviruses from genus beta have
been regarded as likely candidates for a
long time because of their widely
accepted association with cutaneous
SCC in patients with epidermody-
splasia verruciformis (Pfister, 2003).
However, in spite of intriguing
oncogenic and antiapoptotic activities
of betapapillomaviruses (betaPVs), their
significance in skin cancer remains
disputed, mainly because of insufficient
epidemiologic evidence. The retro-
spective follow-up study in this issue
(Genders et al., 2015) provides new
supportive evidence that betaPV do
have a role in skin carcinogenesis. It
shows that betaPV seropositivity around
transplantation implies a significant risk
of developing keratinocyte-derived
malignancy over the following 22
years. There were no associations with
alpha-, gamma-, or nupapillomavirus
seropositivities.
The natural history of betaPV
infections—a nightmare for
epidemiology
An IARC Monograph Working Group in
2009 classified betaPV HPV5 and HPV8
as possibly carcinogenic in epidermo-
dysplasia verruciformis, but it consid-
ered betaPV overall as not classifiable
concerning skin carcinogenicity in gen-
eral. This ‘‘failure’’ is not especially
surprising in view of our current under-
standing that betaPV infects the skin of
probably all people soon after birth as
one element in a well-controlled com-
mensal flora (Weissenborn et al., 2009).
Studies of intrafamilial transmission
have revealed a majority of frequently
exchanged, transient infections and
a minority of persistent types. The
typically missing differentiation bet-
ween transient and persistent infections
has undoubtedly diluted the significance
of epidemiologic case–control studies.
More recently, investigators have tried
to focus on the biologically more rele-
vant betaPV infections, but the defini-
tion of ‘‘biologically relevant infection’’
remains a matter of debate.
Antibody responses to early trans-
forming viral proteins have had limited
investigation. Detectable antibodies to
structural proteins (usually L1) are taken
as indicators of previous infection, suffi-
cient in activity and duration to evoke
an immune response (reviewed in
Genders et al., 2015). Seropositivity
reflects both past and ongoing
HPV infection. To identify ongoing
infections strong enough to evoke an
immune response, Proby et al. (2011)
examined the presence of HPV DNA in
plucked eyebrow hairs. A positive
association was found between SCC
development and concordant DNA
and serum antibody positivity for any
betaPV type (odds ratio (OR) 1.6;
confidence interval (CI) 1.1–2.5) and
for HPV36 (OR 2.4; CI 1.0–5.4).
Organ transplant recipi-
ents have an increased
risk of skin cancer when
seropositive for
betapapillomavirus.
Eyebrow hairs are thought in several
recent epidemiologic studies to be
representative of HPV infection of the
entire skin. BetaPV DNA loads in
plucked eyebrow hairs span seven
orders of magnitude. The top 10% loads
up to 100 HPV DNA copies per cell
approach those observed in patients
with epidermodysplasia verruciformis,
who are at high risk for SCC develop-
ment. Such high loads of viral DNA
have been thought to have also patho-
genic relevance in immunosuppressed
See related article on pg 1275 COMMENTARY
1Institute of Virology, University of Cologne, Cologne, Germany
Correspondence: Herbert Pfister, Institute of Virology, University of Cologne, Fu¨rst-Pu¨ckler-Str.56, Cologne
50935, Germany. E-mail: herbert.pfister@uk-koeln.de
& 2015 The Society for Investigative Dermatology www.jidonline.org 1211
patients and in the general population
(Weissenborn et al., 2012). A case–
control study of OTR showed, indeed,
that patients in the highest cumulative
betaPV DNA load tertile are at a sig-
nificantly higher risk of developing SCC
compared with those in the lowest
tertile. Type-specific risks were identi-
fied for high DNA loads of HPV8, 20,
36, and 38 (Neale et al., 2013).
A breakthrough in prospective studies
A prospective pilot study in 2007 found
no significant differences in betaPV
seroprevalence in controls and inci-
dent SCC cases, when blood was taken
418 months before diagnosis
(Casabonne et al., 2007). This paper
raised the question whether the
increased seroprevalence in cases of
SCC might be a consequence of tumor
formation rather than evidence for
causality. The idea of ‘‘reverse
causality’’ became a long-standing
opinion maker. More recent pro-
spective seroepidemiologic studies
(reviewed by Genders et al., 2015) pro-
vided limited new evidence and could
not identify HPV type–specific risks.
The first prospective study in OTR
(Genders et al., 2015) reports a time-
dependent adjusted hazard ratio of
2.8 (CI 1.3–6.4) for keratinocyte cancer
development related to betaPV
seropositivity, between 1 year before
and 1 year after organ transplantation.
The lack of an association with antibody
responses to alphaPV, gammaPV, and
nuPV is not unexpected. On the other
hand, the association with muPV
seropositivity is surprising, because this
virus genus is so far not thought
to be associated with KCs. It can be
noted that the cumulative cancer
incidence increases linearly after
transplantation for betaPV seropositive
OTR in contrast to a step-wise increase
for seronegative OTR. This might result
from new or reactivated betaPV infec-
tions in the years after transplanta-
tion. Without longitudinal data about
seroconversion one is left with specula-
tion, but if it were true the association
between betaPV and KCs would become
stronger.
As HPV type–specific risk prediction
is rare in the skin cancer field, it is
highly remarkable that HPV8, HPV20,
and HPV75 turned out to be most
relevant for the positive association
between betaPV and all KCs and that
HPV8, HPV20, and HPV76 were asso-
ciated with SCC (Genders et al., 2015).
The controversial association of HPV
in general and betaPV in particular with
BCC is discussed, as more recent studies
have found no correlation (reviewed
by Genders et al., 2015). The current
cohort study reports comparable hazard
ratios for SCC and BCC development
related to betaPV sero-
status. In contrast to SCC, however,
HPV15 was associated with the
development of BCC. These data
suggest that one should not forget
about HPV and BCC completely.
Conclusion and outlook
Papers, such as the one by Genders
et al. (2015), are well suited to shed
light on the relationship between
betaPV and skin cancer. Rapidly
increasing knowledge about the
oncogenic activities of betaPV early
proteins and possible carcinogenic
mechanisms (partially reviewed in
Genders et al., 2015) adds plausibility
to the epidemiologic findings. Taken
together, there is mounting evidence
that betaPV have a role in skin
carcinogenesis.
If confirmed, this mechanistic link
may be exploited for SCC prevention
by anti-viral agents. Proof of principle
for prophylactic vaccination against skin
tumors was recently provided in the
model of betaPV HPV8 transgenic mice
(Marcuzzi et al., 2014). These animals
develop skin tumors spontaneously
within their first year of life.
Mechanical wounding enhances viral
oncogene expression and induces
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Figure 1. Skin tumor prevention by vaccination of HPV8 transgenic skin transplant recipients. The skin from transgenic mice expressing the early genome region
of betapapillomavirus HPV8 in the basal layer of the epidermis was grafted onto non-transgenic littermates. The massive wounding rapidly induced papilloma growth
in the transgenic skin. The non-transgenic recipient skin remained tumor free. Tumor growth in the transplant was prevented, when recipient mice had developed a
measurable immune response after tattooing an HPV8-oncogene E6-DNA vaccine before transplantation (Marcuzzi et al., 2014). As vaccinated mice did not reject the
HPV8-positive transplant, only those keratinocytes appear to be eliminated, as these express higher levels of E6 and would therefore give rise to papillomas.
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papilloma growth within 3 weeks.
When transgenic mouse skin
was transplanted to non-transgenic
littermates, papillomas began to grow
across the transplant surfaces (Figure 1).
In contrast, no papillomas developed
when the recipient mice were immu-
nized successfully with an HPV8-E6-
DNA vaccine before transplanta-
tion. This is, at best, a long-term
perspective for humans, but work in
this area is worth every effort in view
of the great skin cancer burden
observed in allograft recipients who
are immunosuppressed.
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Itch, Eosinophils, and Autoimmunity:
A Novel Murine Model of Bullous
Pemphigoid
Kim B. Yancey1
Mice carrying a deletion in the NC14A domain of murine type XVII collagen begin
scratching at age 2 months and then develop erosions, subepidermal vesicles,
eosinophil-rich skin infiltrates, and autoantibodies directed against a 180 kDa skin
protein that appears to be type XVII collagen. These mice represent a bullous
pemphigoid animal model featuring pruritus in immunocompetent, mature, and
largely unmanipulated animals.
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Type XVII collagen
Type XVII collagen (also called bullous
pemphigoid antigen 2 ;BPAG2) is a type
II transmembrane protein associated
with hemidesmosome-anchoring fila-
ment complexes and plasma mem-
branes in basal keratinocytes (Franzke
et al., 2005). The cytoplasmic amino
terminus of type XVII collagen consists
of B500 amino acid residues, contain-
ing several potential phosphorylation
sites within its central portion; by
rotary shadowing, the intracytoplasmic
domain of type XVII collagen appears
as a globular head. The extracellular
domain of type XVII collagen
contains 15 interrupted collagenous
segments (coll 1–15); by rotary
shadowing, the extracellular domain of
type XVII collagen appears as a central
rod (corresponding to coll 15) with a
flexible tail (corresponding to coll 1–14)
(Hirako et al., 1996). Immunoelectron
microscopy studies suggest that the rod
portion of type XVII collagen’s
ectodomain (i.e., coll 15) inserts into
the lamina densa and that its carboxy-
terminal flexible tail then loops back
through the lamina densa into the
lamina lucida (Nonaka et al., 2000).
Type XVII collagen occurs in two
forms, a 180kDa full-length protein
and a 120kDa extracellular domain that
is shed from plasma membranes of basal
keratinocytes by proteolysis (Schacke
et al., 1998). Proteolytic processing of
type XVII collagen is mediated by
‘‘sheddases’’ of the disintegrin and
metalloproteinase family. Phosphoryla-
tion of type XVII collagen by ecto-casein
kinase 2 inhibits its proteolysis, a
mechanism whereby the adhesion and
motility of adjacent basal keratinocytes
may be modulated (Zimina et al., 2007).
In epidermal basement membranes
(BMs), the extracellular domain of type
XVII collagen is found as a homotrimer
in which its collagenous domains form a
cross-linked triple helix. The helix forms
independently of amino acid sequences
in its intracellular portion, apparently
organized in a 50 to 30 orientation
using the 16th non-collagenous portion
of the protein (the 16th non- colla-
genous domain of BPAG2 (NC16)) as a
nucleation site. The cytoplasmic
domain of type XVII collagen
associates with BPAG1, integrin b4,
and plectin. The first extracellular
segment of type XVII collagen (i.e.,
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